Alemtuzumab is indicated for:
Population group: both men and women, only adults (18 years old or older)
Alemtuzumab is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Alemtuzumab is contraindicated in the following cases: